Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients
- Hilke Zander†1Email author,
- Tamina Rawnaq†1,
- Max von Wedemeyer1,
- Michael Tachezy1,
- Miriam Kunkel1,
- Gerrit Wolters1,
- Maximilian Bockhorn1,
- Melitta Schachner2,
- Jakob R Izbicki1 and
- Jussuf Kaifi1
© Zander et al; licensee BioMed Central Ltd. 2011
Received: 21 September 2010
Accepted: 22 May 2011
Published: 22 May 2011
L1 cell adhesion molecule (CD171) is expressed in many malignant tumors and its expression correlates with unfavourable outcome. It thus represents a target for tumor diagnosis and therapy. An earlier study conducted by our group identified L1 expression levels in primary gastrointestinal stromal tumors (GIST) as a prognostic marker. The aim of the current study was to compare L1 serum levels of GIST patients with those of healthy controls and to determine whether levels of soluble L1 in sera could serve as a prognostic marker.
Using a sensitive enzyme-linked immunosorbent assay (ELISA), soluble L1 was measured in sera of 93 GIST patients und 151 healthy controls. Soluble L1 levels were then correlated with clinicopathological data.
Median levels of soluble L1 were significantly higher (p < 0.001; Mann-Whitney U test) in sera of GIST patients compared to healthy individuals. Median soluble L1 levels were particularly elevated in patients with recurrence and relapse (p < 0.05; Mann Whitney U test).
These results suggest that high soluble L1 levels predict poor prognosis and may thus be a promising tumor marker that can contribute to individualise therapy.
KeywordsGastrointestinal stromal tumor (GIST) L1 Enzyme-linked Immunosorbent assay (ELISA) progression marker
Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal mesenchymal tumors with an incidence of 10-13 per million people a year . They are mostly discovered incidentally during endoscopic or surgical procedures or are diagnosed in the evaluation of patients suffering from abdominal pain or/and upper gastrointestinal bleeding. GISTs occur most frequently in the stomach and small intestine, but rarely in the esophagus and colorectum [2, 3]. GISTs are thought to arise from common precursor cells of the interstitial cells of Cajal (ICC) from the muscular plexus in the gut wall . Following the consensus approach of 2002, they are classified according to tumor size and mitotic index . After surgical resection the outcome of GIST is correlated with size and mitotic count and patients with recurrence have a worse prognosis . Activating mutations in the tyrosine kinase c-kit (CD117) gene and platelet-derived growth factor receptor α gene (PDGFRα) have been reported to play important roles in the progression and diagnosis of GISTs [7, 8]. First line therapy for unresectable or metastatic GISTs by molecular targeting with the tyrosine kinase inhibitor imatinib (Glivec ®) has been shown in clinical trials to be efficacious and well tolerated .
There is to date no prognostic serum marker for GISTs. One possible candidate is the neuronal cell adhesion molecule L1 (CD171), which is expressed in primary tumors in 74% of cases . L1 is a 200-220 kDa multidomain type 1 membrane glycoprotein of the immunoglobulin superfamily which plays a central role in neural development and regeneration and in synaptic plasticity in the adult nervous system [11, 12]. It affects neuron-neuron adhesion and neurite outgrowth on Schwann cells as well as neurite fasciculation and myelination . The extracellular domain of L1 can be regulatorily cleaved from the tumor cell surface in a process called shedding. Several L1 processing proteases could be identified such as members of a disintegrin and metallprotease ADAM10, ADAM17 [14, 15] and PC5A . The shed and solubilised extracellular domain is able to mediate L1 signal transduction via homo- and heterophilic interactions . Among others L1 binds integrins and other members of the L1 family, such as CHL1 and NrCAM [18–20].
L1 overexpression has been detected in various tumor cell types of neural, mesothelial, and epithelial origin. Expression profile analysis in multiple human tumors has identified L1 as a molecular marker for differential diagnosis and targeted therapy [21, 22]. Its presence in tumors and sera has a prognostic significance in ovarian, uterine and renal cell carcinomas and is associated with metastasis of melanomas [23–25].
The aim of this study was to evaluate whether soluble L1 could serve as diagnostic marker and prognostic factor in GIST patients by correlating L1 serum levels to long-term outcome.
Study design and patients
The study was approved by the Ethics Committee of the Chamber of Physicians in Hamburg, Germany. Written informed consent was obtained from all patients for using tissue and serum samples. For this study, 93 patients with GIST were chosen retrospectively. It was possible to evaluate a rather large number of patients suffering from this rare tumor because of the cooperation of a self-help organization for GIST patients called "Lebenshaus e.v.", Bad Nauheim, Germany, which helped to collect serial serum samples from patients across Germany, Austria and Switzerland. The blood samples were taken from patients at time of diagnosis and every 3 months thereafter. We selected patients on the basis of availability of specimens and did not stratify them due to rare occurrence and different treatment strategies. All data including sex, age, tumor size, mitotic count, tumor location, metastasis, relapse, and imatinib therapy were obtained from the clinical and pathological records. The clinicopathological data from externally treated patients participating in the self-help project were sent regularly by their attending physicians. As healthy controls, 151 blood bank donors were included in the study. Limitations in this study were that we had some missing items in the clinical and pathological data of our patients due to logistic difficulties in collecting data of patients from different hospitals. However, a sufficient number of GIST patients were included in the study.
ELISA for the detection of soluble human L1
For the detection of soluble L1, 96-well flexible microtiter plates (Costar 9019) were coated with 50 μl per well of 10 μg/ml of capturing antibody (anti-L1 mAb 5G3, BD Bioscience) overnight at 4°C. Wells were blocked with 3% w/v bovine serum albumin (BSA; Fraktion V, 98% purity, Sigma Aldrich, Munich, Germany) in PBS/T (phosphate buffered saline, pH 7.3, containing 0.05% v/v Tween) for 45 min at room temperature and then incubated for 1 h with human sera diluted 1:5 in PBS at room temperature. After five washes with PBS/T, bound protein was detected with biotin-conjugated monoclonal antibody UJ127 (Dianova, Hamburg, Germany)- which does not cross-react with the close homolog of L1 (chL1) - followed by streptavidin-conjugated peroxidase using TMB (3,3', 5,5"-tetramethylbenzidine) as substrate. The color reaction was stopped by the addition of 10 mM H2SO4 and analysed at 450 nm using an ELISA reader. Human L1-Fc protein served as an internal standard for the assay.
To ensure that the immunoassay was suitable for measuring clinical serum samples, reproducibility, linearity and crossreactivity were examined. The assay showed no crossreactivity with the closed homolog of L1 CHL1, excellent linearity with serial dilutions and a low coefficient of variation (CV) in intra- and inter-assay variability.
Sample preparation and Western blot analysis
For analysis of L1cam protein, PBS washed GIST882 cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM Na4P2O7, 1 mM NaF, 1 mM EDTA, 2 mM Na3VO4, 1 mM PMSF, 1% NP-40 plus complete EDTA-free protease inhibitor mixture, pH 7.5) for 30 min at 4°C and then subjected to SDS-Page and Western blot analysis. Equal amount of protein of each sample was mixed with 2x Laemmli Buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue, 0.125 M Tris HCl, pH 6.8) and boiled at 95°C for 5 min. Protein extracts were separated by 4 - 12% SDS-PAGE (NuPage, Invitrogen, Karlsruhe, Germany) and transferred onto nitrocellulose membrane (Protran; Whatman Schleicher and Schuell Dassel, Germany). For immunoblotting, membranes were blocked with StartingBlock (TBS) Blocking Buffer (Pierce, Rockford, IL, USA) and incubated overnight at 4°C with primary 1:1000 biotinylated antibody L1-UJ127 (Dianova, Hamburg Germany). UJ127 binds to a membrane proximal Fn repeat. This allows detection of both the ADAM-cleaved 180 kDa shed fragment and the 80 kDa membrane-bound fragment presumably generated by plasmin cleavage. After washes with TBST (TBS with 0.1% Tween 20), membranes were incubated with HRP-conjugated streptavidin (Sigma Aldrich, Munich, Germany) (1:500) for 1 h at room temperature. After extensive washes, streptavidin-reactive bands were visualized using enhanced chemiluminescent substrate (ECL, Pierce) on x-ray films (Kodak Biomax-ML; Sigma-Aldrich, Munich, Germany).
SPSS® for Windows (Version 11.5.1) (SPSS® Inc., Chicago, IL, USA) was used for statistical analysis. Statistical significance was evaluated by the Mann-Whitney U and Kruskal-Wallis test. Cross-table statistics were performed using Fisher's test. Recurrence-free survival was plotted using the Kaplan-Meier method and analysed by the log-rank test. Significance statements refer to p-values of two-tailed tests less than 0.05.
Characteristics of patients and healthy controls
Clinicopathological characteristics of GIST patients (n = 93) and soluble L1 concentrations
Absolute counts (%)
Median soluble L1 concentration (25th and 75th percentile (ng/ml))
Mean soluble L1 concentration ± SD (ng/ml)
1.4 (0.8 and 2.7)
2.1 ± 2.4
0.5 (0.0 and 1.0)
0.7 ± 1.4
1.5 (0.8 and 2.7)
2.1 ± 2.6
1.3 (0.8 and 2.4)
2 ± 2.3
Tumor size (cm)
1.4 (0.9 and 4.8)
2.9 ± 3
1.7 (1 and 2.4)
2.2 ± 2.2
1.2 (0.7 and 2.4)
1.9 ± 2.1
1 (0.4 and 2)
1.4 ± 1.4
Mitotic count (per 50 HPF)
1.1 (0.6 and 1.9)
1.7 ± 2.1
1.1 (0.7 and 2)
1.3 ± 0.8
1.7 (1.1 and 2.6)
1.9 ± 1.2
1.4 (0.9 and 2.6)
2.0 ± 2.0
1.5 (0.6 and 2.6)
1.8 ± 2
1.1 (0.5 and 3.2)
1.7 ± 1.5
1.4(0.8 and 2.6)
2.1 ± 0.4
1.4(1.2 and 2.6)
2.0 ± 0.4
1.1 (0.8 and 1.7)
1.4 ± 1.2
1.7 (0.9 and 3)
2.4 ± 2.3
1.4 (0.8 and 3.0)
2.4 ± 2.7
1.5 (0.7 and 2.4)
1.6 ± 1.2
Risk NIH criteria
1.2 (0.7 and 2.8)
1.7 ± 1.4
1.1 (0.8 and 1.9)
1.4 ± 1.0
0.7 (0.3 and 2.4)
2.0 ± 3.0
1.5 (0.8 and 2.4)
1.7 ± 1.4
Risk AFIP criteria
1.2 (0.7 and 2.8)
1.7 ± 1.4
1.4 (0.9 and 2.2)
1.8 ± 1.4
0.7 (0.2 and 2.0)
1.9 ± 2.8
1.5 (1.0 and 2.6)
1.6 ± 1.1
Soluble-L1 concentrations of healthy controls and GIST patients
Increased soluble L1 serum concentrations correlate with recurrence and negative outcome
Table 1 shows that GIST patients with recurrence had significantly higher median soluble L1 concentrations than those without. Soluble L1 concentration (25th and 75th percentiles) was 1.7 (0.9 and 3) ng/ml in GIST patients with recurrence and 1.1 (0.8 and 1.7) ng/ml in relapse-free patients (p = 0.049; Mann-Whitney U test).
Neither mitotic count nor tumor size had an influence on recurrence-free survival plotted by Kaplan-Meier analyses (p = 0.231 and p = 0.199, log rank test; data not shown). Also mitotic count and tumor size could not be significantly correlated with recurrence (p = 0.075 and p = 0.725, Fisher's test).
Most primary cancers develop loss of expression of adhesion molecules. This allows for a critical step in metastasis to occur: detachment of the invading cell from its neighbors [27, 28]. Some adhesion molecules, such as L1, however show elevated expression in some tumor entities. There are several potential interpretations for this phenomenon. Increased homophilic intercellular adhesion may favor the metastatic process because cell aggregates, rather than single cells breaking away from the primary tumor, have a greater chance of surviving in the circulation and of lodging in other organs . Furthermore it is known that cell adhesion is necessary for the metastatic spread of cancer cells to new organs . It was shown that L1 expressed on tumor endothelium could favor metastasis and angiogenesis . The development of new blood vessels is a key step of tumor progression that might be promoted by the interaction of proteolytically cleaved soluble forms of L1 with integrins . The shed L1 can promote L1 dependent homophilic stimulation in an autocrine fashion . The proteolytic events not only take place on the cell surface but also on membrane vesicles such as exosomes and apoptotic membrane vesicles . This can explain the detection of full length and shed L1 in sera.
In a previous study we could show that L1 expression was immunohistochemically detectable in 74% of GISTs, but not in differential diagnostic important tumors such as smooth muscle tumor, peripheral nerve sheath tumor or desmoid-type fibromatosis. Although c-kit expression is the etablished standard in the identification of GIST, additional prognostic markers are beneficial. To date, most studies regarding L1 expression have been performed at the mRNA level or by immunohistochemistry. To evaluate the role of L1 as a peripheral marker, we here examined L1 levels in serum of GIST patients and healthy controls.
Using a specifically developed robust and highly sensitive immunoassay we were able to demonstrate that soluble L1 concentrations were significantly elevated in the blood of GIST patients compared to a healthy control group and other gastric tumors. Furthermore, we observed a significant association between increased soluble L1 levels and recurrence, which predicts worse outcome in GIST. Patients with high soluble L1 concentrations had a poorer recurrence-free survival than patients with lower levels. These observations are in agreement with our previous immunohistochemical study, where a trend towards worse outcome of patients with L1-positive tumors was reported [10, 34]. Elevated soluble L1 as a negative prognostic marker has already been shown for some types of ovarian cancers . In melanoma and ovarian carcinoma the cleaved L1CAM ectodomain can play a role in tumor progression, conferring cellular properties that are important in advanced stages of cancer progression including enhanced motility and invasivenes [33, 35]. Our study suggests that also in GIST, high L1 serum levels are leading to high cell dispersal of the tumor which augments the risk of recurrence.
Soluble L1 concentration could thus become a useful marker for tumor progression and metastasis, which predicts prognosis in GIST.
Our results also suggest that L1 may be an important therapeutic target in the treatment of GIST. The efficiency of L1 monoclonal antibody treatment in suppressing tumor growth has been described in nude mice, where intraperitoneal injection of an L1 antibody was found to inhibit intraperitoneal tumor proliferation and dissemination of malignant tumor cells . In this context it might be relevant that soluble L1 levels depend on the presence of proteinases. Matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs) are involved in many aspects of tumor biology. ADAM17, which has been shown to mediate L1 cleavage  has also been identified as a major sheddase in GIST .
We provide evidence that analysis of serum concentrations of soluble L1, comprising the extracellular domain of the L1 molecule, represents a novel and useful approach to assess the malignancy and metastatic potential of GISTs. The availability of a reliable immunoassay, such as the one developed for this study, for measuring serum L1 concentrations will facilitate further studies to establish the clinical applicability of this marker in GISTs and other tumors. These studies should notably investigate L1 levels in other serum samples such as obtained pre- and post-surgery and serially during the course of therapy. Beyond clinical applicability, future work must address mechanistic questions about the functional role of L1 in the tumorigenesis of GISTs and other L1 expressing cancers.
This study was funded by research grants from the Dr. Mildred Scheel Stiftung (German Cancer Aid) to J.K. and M.S. and supported by Novartis Oncology.
We thank the patients who willingly and generously provided data and samples for research purposes as well as Petra Schroeder for her technical support.
- Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schoffski P: Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. Semin Oncol. 2009, 36 (4): 290-301. 10.1053/j.seminoncol.2009.06.002.View ArticlePubMedGoogle Scholar
- Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002, 38 (Suppl 5): S39-51.View ArticlePubMedGoogle Scholar
- Miettinen M, Paal E, Lasota J, Sobin LH: Gastrointestinal glomus tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 32 cases. Am J Surg Pathol. 2002, 26 (3): 301-311. 10.1097/00000478-200203000-00003.View ArticlePubMedGoogle Scholar
- Fletcher CD: Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol. 2002, 33 (5): 455-10.1053/hupa.2002.124119.View ArticlePubMedGoogle Scholar
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002, 10 (2): 81-89. 10.1177/106689690201000201.View ArticlePubMedGoogle Scholar
- Miettinen M, El-Rifai W, L HLS, Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002, 33 (5): 478-483. 10.1053/hupa.2002.124123.View ArticlePubMedGoogle Scholar
- Demetri GD: Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002, 38 (Suppl 5): S52-59.View ArticlePubMedGoogle Scholar
- Fletcher CD, Fletcher JA: Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest?. Appl Immunohistochem Mol Morphol. 2002, 10 (3): 197-198. 10.1097/00022744-200209000-00001.PubMedGoogle Scholar
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347 (7): 472-480. 10.1056/NEJMoa020461.View ArticlePubMedGoogle Scholar
- Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR: L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol. 2006, 19 (3): 399-406. 10.1038/modpathol.3800547.View ArticlePubMedGoogle Scholar
- Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M: Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature. 1988, 334 (6184): 701-703. 10.1038/334701a0.View ArticlePubMedGoogle Scholar
- Rathjen FG, Schachner M: Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J. 1984, 3 (1): 1-10.PubMedPubMed CentralGoogle Scholar
- Maness PF, Schachner M: Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci. 2007, 10 (1): 19-26. 10.1038/nn1827.View ArticlePubMedGoogle Scholar
- Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Gast D, Joumaa S, Zentgraf H, Fogel M, Altevogt DP: ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. Faseb J. 2003, 17 (2): 292-294.PubMedGoogle Scholar
- Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P, Reiss K: L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol. 2005, 25 (20): 9040-9053. 10.1128/MCB.25.20.9040-9053.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Kalus I, Schnegelsberg B, Seidah NG, Kleene R, Schachner M: The proprotein convertase PC5A and a metalloprotease are involved in the proteolytic processing of the neural adhesion molecule L1. J Biol Chem. 2003, 278 (12): 10381-10388. 10.1074/jbc.M208351200.View ArticlePubMedGoogle Scholar
- Lemmon V, Farr KL, Lagenaur C: L1-mediated axon outgrowth occurs via a homophilic binding mechanism. Neuron. 1989, 2 (6): 1597-1603. 10.1016/0896-6273(89)90048-2.View ArticlePubMedGoogle Scholar
- Brummendorf T, Rathjen FG: Axonal glycoproteins with immunoglobulin- and fibronectin type III-related domains in vertebrates: structural features, binding activities, and signal transduction. J Neurochem. 1993, 61 (4): 1207-1219. 10.1111/j.1471-4159.1993.tb13611.x.View ArticlePubMedGoogle Scholar
- Ruppert M, Aigner S, Hubbe M, Yagita H, Altevogt P: The L1 adhesion molecule is a cellular ligand for VLA-5. J Cell Biol. 1995, 131 (6 Pt 2): 1881-1891.View ArticlePubMedGoogle Scholar
- Hillenbrand R, Molthagen M, Montag D, Schachner M: The close homologue of the neural adhesion molecule L1 (CHL1): patterns of expression and promotion of neurite outgrowth by heterophilic interactions. Eur J Neurosci. 1999, 11 (3): 813-826. 10.1046/j.1460-9568.1999.00496.x.View ArticlePubMedGoogle Scholar
- Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H: The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res. 2005, 11 (3): 1190-1197.PubMedGoogle Scholar
- Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P: L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 2003, 189 (2): 237-247. 10.1016/S0304-3835(02)00513-X.View ArticlePubMedGoogle Scholar
- Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G, Schumacher U: Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer. 2002, 38 (13): 1708-1716. 10.1016/S0959-8049(02)00105-3.View ArticlePubMedGoogle Scholar
- Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG, Cavallaro U: The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res. 2008, 68 (4): 1110-1118. 10.1158/0008-5472.CAN-07-2897.View ArticlePubMedGoogle Scholar
- Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet. 2003, 362 (9387): 869-875. 10.1016/S0140-6736(03)14342-5.View ArticlePubMedGoogle Scholar
- Bauer S, Yu LK, Demetri GD, Fletcher JA: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006, 66 (18): 9153-9161. 10.1158/0008-5472.CAN-06-0165.View ArticlePubMedGoogle Scholar
- Sommers CL: The role of cadherin-mediated adhesion in breast cancer. J Mammary Gland Biol Neoplasia. 1996, 1 (2): 219-229. 10.1007/BF02013645.View ArticlePubMedGoogle Scholar
- Stoll BA: Biological mechanisms in breast cancer invasiveness: relevance to preventive interventions. Eur J Cancer Prev. 2000, 9 (2): 73-79. 10.1097/00008469-200004000-00002.View ArticlePubMedGoogle Scholar
- Updyke TV, Nicolson GL: Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential. Clin Exp Metastasis. 1986, 4 (4): 273-284. 10.1007/BF00133592.View ArticlePubMedGoogle Scholar
- Issa Y, Nummer D, Seibel T, Muerkoster SS, Koch M, Schmitz-Winnenthal FH, Galindo L, Weitz J, Beckhove P, Altevogt P: Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med. 2009, 87 (1): 99-112. 10.1007/s00109-008-0410-7.View ArticlePubMedGoogle Scholar
- Friedli A, Fischer E, Novak-Hofer I, Cohrs S, Ballmer-Hofer K, Schubiger PA, Schibli R, Grunberg J: The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor. Int J Biochem Cell Biol. 2009, 41 (7): 1572-1580. 10.1016/j.biocel.2009.01.006.View ArticlePubMedGoogle Scholar
- Mechtersheimer S, Gutwein P, Agmon-Levin N, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V, Altevogt P: Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol. 2001, 155 (4): 661-673. 10.1083/jcb.200101099.View ArticlePubMedPubMed CentralGoogle Scholar
- Stoeck A, Keller S, Riedle S, Sanderson MP, Runz S, Le Naour F, Gutwein P, Ludwig A, Rubinstein E, Altevogt P: A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J. 2006, 393 (Pt 3): 609-618.View ArticlePubMedPubMed CentralGoogle Scholar
- Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, Izbicki JR: L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol. 2007, 20 (11): 1183-1190. 10.1038/modpathol.3800955.View ArticlePubMedGoogle Scholar
- Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marme A, Phong MC, Linderkamp O, Skorokhod A, Altevogt P: Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res. 2005, 11 (7): 2492-2501. 10.1158/1078-0432.CCR-04-1688.View ArticlePubMedGoogle Scholar
- Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P, Kruger A: Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006, 66 (2): 936-943. 10.1158/0008-5472.CAN-05-1818.View ArticlePubMedGoogle Scholar
- Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, Tani H, Yamashita Y, Iwasaki H: Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci. 2009, 100 (4): 654-662. 10.1111/j.1349-7006.2009.01089.x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/189/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.